BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of chalcone derivatives as potent and orally active hCYP3A4 inhibitors. 2023

Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
School of Pharmacy, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; State Key Laboratory of Drug Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.

Human cytochrome P450 3A4 (hCYP3A4), one of the most important drug-metabolizing enzymes, catalyze the metabolic clearance of ∼50% therapeutic drugs. CYP3A4 inhibitors have been used for improving the in vivo efficacy of hCYP3A4-substrate drugs. However, most of existing hCYP3A4 inhibitors may trigger serious adverse effects or undesirable effects on endogenous metabolism. This study aimed to discover potent and orally active hCYP3A4 inhibitors from chalcone derivatives and to test their anti-hCYP3A4 effects both in vitro and in vivo. Following three rounds of screening and structural optimization, the isoquinoline chalcones were found with excellently anti-hCYP3A4 effects. SAR studies showed that introducing an isoquinoline ring on the A-ring significantly enhanced anti-CYP3A4 effect, generating A10 (IC50 = 102.10 nM) as a promising lead compound. The 2nd round of SAR studies showed that introducing a substituent group at the para position of the carbonyl group on B-ring strongly improved the anti-CYP3A4 effect. As a result, C6 was identified as the most potent hCYP3A4 inhibitor (IC50 = 43.93 nM) in human liver microsomes (HLMs). C6 also displayed potent anti-hCYP3A4 effect in living cells (IC50 = 153.00 nM), which was superior to the positive inhibitor ketoconazole (IC50 = 251.00 nM). Mechanistic studies revealed that C6 could potently inhibit CYP3A4-catalyzed N-ethyl-1,8-naphthalimide (NEN) hydroxylation in a competitive manner (Ki = 30.00 nM). Moreover, C6 exhibited suitable metabolic stability in HLMs and showed good safety profiles in mice. In vivo tests demonstrated that C6 (100 mg/kg, orally administration) significantly increased the AUC(0-inf) of midazolam by 3.63-fold, and strongly prolonged its half-life by 1.66-fold compared with the vehicle group in mice. Collectively, our findings revealed the SARs of chalcone derivatives as hCYP3A4 inhibitors and offered several potent chalcone-type hCYP3A4 inhibitors, while C6 could serve as a good lead compound for developing novel, orally active CYP3A4 inhibitors with improved druglikeness properties.

UI MeSH Term Description Entries

Related Publications

Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Design, synthesis and biological evaluation of indanone-chalcone hybrids as potent and selective hCES2A inhibitors.
January 2021, European journal of medicinal chemistry,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors.
March 2020, Bioorganic & medicinal chemistry,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors.
January 2023, Bioorganic & medicinal chemistry,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Design, synthesis and biological evaluation of dihydrofurocoumarin derivatives as potent neuraminidase inhibitors.
April 2021, Bioorganic & medicinal chemistry letters,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Design, Synthesis, and Biological Evaluation of Chalcone-Containing Shikonin Derivatives as Inhibitors of Tubulin Polymerization.
March 2017, ChemMedChem,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors.
November 2014, Bioorganic & medicinal chemistry,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
June 2007, Bioorganic & medicinal chemistry,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.
February 2007, Bioorganic & medicinal chemistry,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors.
November 2004, Bioorganic & medicinal chemistry,
Shiwei Lu, and Feng Zhang, and Jiahao Gong, and Jian Huang, and Guanghao Zhu, and Yitian Zhao, and Qi Jia, and Yiming Li, and Bo Li, and Kaixian Chen, and Weiliang Zhu, and Guangbo Ge
Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.
November 2023, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!